Evidence map›Paper›PMID 42834336›Full record

ArticleActa ophthalmologica2026

Insights into the modulation of age-related macular degeneration: Molecular and systems-level perspectives.

Hanna Heloterä

Abstract read
In one paragraph

Article in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hanna HeloteräOphthalmology, Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Funding

Aarne Koskelon SäätiöMary och Georg C. Ehrnrooths StiftelseSuomen silmä- ja kudospankkisäätiö
6 · The paper itself

Abstract

In developed countries, age-related macular degeneration (AMD) is the leading cause of visual impairment in the aging population. Understanding of its pathogenesis is limited and the number of patients is predicted to continue rising. AMD is classified into two main forms: dry and neovascular AMD (dAMD and nAMD, respectively). Dry AMD is the most prevalent form (80-90%) of AMD cases and has no approved treatment in Europe. Neovascular AMD (10-20% of AMD cases) is treated with frequent intravitreal injections with medicines intervening with vascular growth, but unfortunately, treatment is not curative and only a portion of patients respond to the current treatments. Increasing number of patients will create a challenge to the healthcare system and will underline the need to find either novel, more durable treatment options or ways to intervene with the disease course already in its early stages and prevent or delay disease escalation. Thus, understanding factors behind development of the disease and treatment response is important. Currently, the information on the factors influencing the progression and incidence of the disease is fragmented and does not provide sufficient tools for individualised patient care. In this study, our aim was to create a deeper understanding of factors modulating development and progression of AMD. By analysing data from nAMD patients treated in Kuopio University Hospital, we were able to identify that heavy smoking and high BMI increase the probability for earlier emergence of nAMD, while the presence of intraretinal fluid (IRF) resulted in a fast-progressing disease. We also observed a relationship between IRF and the appearance of subretinal drusenoid deposits, HRF and retinal atrophy. Thus, we observed that IRF plays a role in the escalation of the disease towards non-reversible changes in retinal anatomy. By analysing serum RNA profile of nAMD patients, we observed that the RNA profile of nAMD patients corresponds with anatomical changes observed in the retinal fluid compartments as well as atrophic changes in retinal layers. Especially, thioredoxin-related transmembrane protein 4 (TMX4) was identified as a protein whose function during AMD development should be evaluated more in detail in the future. Moreover, long-term follow-up of women living in the North Savo region revealed the role of systemic components during AMD progression and showed that people with long-term corticosteroid and immunosuppressant use have an increased risk for developing AMD. Our results highlight that further research on how systemic components behind corticosteroid and immunosuppressant use modulate AMD progression is needed. Thus, results of this study build more evidence from factors modulating AMD development and progression. Giving guidance to future analyses in a situation where comprehensive understanding from factors influencing AMD progression and development are lacking.

Indexed as

Wet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsDisease ProgressionFemaleFluorescein AngiographyHumansIntravitreal InjectionsMaleTomography, Optical CoherenceAngiogenesis Inhibitorsage‐related macular degenerationagingretinal pigment epithelium

Identifiers

PMID42834336
PMCPMC13638769

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.